Chubb Ltd vs Moderna, Inc. — how do they compare? Chubb Ltd trades at $347.09 (market cap $134.37B), while Moderna, Inc. trades at $60.53 (market cap $23.88B). The key difference: Chubb Ltd is far larger — about 5.6× Moderna, Inc.'s market cap, and Chubb Ltd pays a 1.17% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| CB | MRNA | |
|---|---|---|
Market Cap | $134.37B | $23.88B |
Sector | Financials | Health |
52-Week High | $363.50 | $81.80 |
52-Week Low | $268.20 | $22.36 |
Enterprise Value | $155.22B | $20.03B |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $350.31, down 1.05% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $7.26 beating estimates, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Recent news highlights leadership appointments and positive earnings coverage.
The outlook is positive, supported by consistent earnings beats, a 52.38% analyst buy rating, and a consensus price target of $366.83. Risks include macroeconomic sensitivity and competitive pressures in insurance. The stock presents a value opportunity with a P/E of 12.41 and robust cash flow trends.
Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.
The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →